AttgeNO (private company)

See something wrong or missing? Let us know
Offices:Stockholm
Business model:B2B

AttgeNO is working on the development of new blood vessel-inducing drugs. Supernitro (PDNO) is a new patented drug candidate for the treatment of acute life threatening high blood pressure in the lung, which may occur in conjunction with cardiac surgery and fatal outcome.

Investors: we tracked 2 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 3.44M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to AttgeNO

Name Criteria
Sweden Saga Diagnostics
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Hadean Ventures
  • Total raised in a similar range: 1M - 5M USD
Denmark Galecto Biotech
53%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Hadean Ventures
Sweden Gesynta Pharma
53%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one vc investor: Hadean Ventures
Norway Oncoinvent
53%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Hadean Ventures
Norway Nisonic
50%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Hadean Ventures
  • Total raised in a similar range: 1M - 5M USD
France ABC Transfer
48%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
France AbolerIS Pharma
48%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Norway APIM Therapeutics
48%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Spain AptaTargets
48%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Sweden Athera
48%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Top